According to a secondary analysis of the 24- Month Myopia Outcome Study of Atropine in Children (MOSAIC) trial, 0.05% atropine eye drops were more efficient in managing myopia development and axial elongation than placebo eye drops in kids regardless of triggering blurred vision and photophobia in some individuals.
- Scientist carried out a secondary analysis of the 3-year outcomes of the MOSAIC trial to examine the effectiveness and security of various atropine routines in treatment-naive kids aged 6-16 years with a round comparable ≤ − 0.50 diopters (D).
- They evaluated information of 199 kids in Europe with myopia (mean age, 13.9 years; 60.8% women) who were arbitrarily appointed to either group 1 (nighttime placebo for 2 years followed by 0.05% atropine eye drops for 1 year; n = 66) or group 2 (nighttime 0.01% atropine eye drops for 2 years followed by another random project to nighttime placebo, tapering placebo, or tapering of 0.01% atropine eye drops for 1 year; n = 133).
- The nighttime and tapered placebo groups were integrated as a single treatment group for the sake of analysis.
- The main result procedures consisted of observed modifications in the development of myopia, examined utilizing cycloplegic round comparable refraction and axial length from month 24 to month 36.
TAKEAWAY:
- Kids in the 0.01% atropine then placebo groups revealed higher round equivalent development (changed distinction, − 0.13 D; P =.01) and axial elongation (changed distinction, 0.06 mm; P =.008) than those in the placebo then 0.05% atropine group.
- Kids in the placebo then 0.05% atropine group likewise experienced less axial elongation (P =.04) than those in the 0.01% atropine then tapering 0.01% atropine group.
- Amongst individuals utilizing 0.05% atropine, 15% reported blurred near vision and 8% reported photophobia, whereas 3% reported blurred near vision and 0% reported photophobia in the 0.01% atropine then tapering 0.01% atropine group.
- Regardless of experiencing unfavorable occasions, no individuals in the placebo then 0.05% atropine group terminated treatment, with 92% finishing the 36-month check out and 81% sticking to the treatment program.
IN PRACTICE:
“Recognizing a 2-year hold-up in treatment initiation in the group of kids initially designated to placebo, 0.05% atropine eyedrops slowed both myopia development and axial eye development throughout a 1-year duration,” the authors of the research study composed.
This research study was led by James Loughman, PhD, of the Centre for Eye Research Ireland in Dublin, Ireland. It was released online on January 9, 2025, in JAMA Ophthalmology
Limitations consisted of smaller sized sample sizes throughout treatment groups in year 3 and possible carry-over impacts for individuals transitioning from 0.01% atropine to placebo or tapered dosing. Due to the fact that the research study did not have a without treatment control group, rebound myopia development might be determined based just on the anticipated 3rd-year arise from the 0.01% atropine then placebo groups. The age of individuals throughout the 3rd year might have impacted the capability to identify rebound development.